Comprehensive Safety & Toxicology Services

Southern Research develops and manages nonclinical safety and pharmacokinetic studies to help our clients understand margins of safety and to bring novel therapeutics to the clinic.

SR-Viral-Therapy-Hero-1

Your Gateway to Nonclinical Toxicology Expertise

Our toxicologists have decades of experience in the safety testing of small molecules, biologics, and novel therapeutics for the treatment of cancer. Vaccine safety and mRNA therapeutics have also been a major focus at Southern Research since the COVID-19 pandemic. Our team also have extensive experience with vectored vaccines and oncolytic viruses to treat cancer.

Our clinical pathology, immunology and in-vitro capabilities allow us to measure effects on the immune system by flow cytometry as well as anti-drug antibodies by ELISA, mRNA levels by PCR, and blood cytokine levels by Luminex and Mesoscale Discovery.

Our internal partnership with our Infectious Disease Department allows us to conduct efficacy and toxicity studies under biosafety level 3 containment. We have worked with government agencies to test novel vaccine delivery technologies, such as microneedle array patches and the reproductive safety of drugs and plant-derived dietary supplements. We offer standard PK, dose range-finding, and repeat dose GLP studies in small and large animal models, as well as biodistribution and neurovirulence testing of vaccines. Standard routes of administration include dermal, oral, intravenous, intradermal, intramuscular, intracranial, intranasal, intrathecal, and subcutaneous.

Our Toxicology Services

General Toxicology

IND-Enabling Services

Genetic Toxicology

Toxicokinetics

Safety Toxicology

Specialized Toxicology

SEND Datasets

Revealing the Nonclinical Safety Profile

Unwavering Commitment to Quality and Client Satisfaction

Our toxicology studies and IND-enabling programs are tailored to the type of molecule being developed, relevant regulatory guidance, and with the planned clinical treatment regimen in mind. We help our clients de-risk their molecules and understand FDA and EMA feedback related to the next stage of drug development.

FDA and ICH guidance documents and GLP regulations provide directive on the design and conduct of toxicology studies at our AALAC accredited animal facility. Our board-certified veterinary pathologists put their findings in context of overall health and our historical control database. Clients come to Southern Research for a customer-focused experience where knowledge and quality meet operational excellence.

Our Toxicology Experts

Joseph Randall, Ph.D.

Director of Toxicology

Erin Luea

Senior Scientist

Partner With Us

Let us be your trusted partner in navigating the complexities of preclinical toxicology research. Our comprehensive preclinical toxicology services, combined with our unwavering commitment to quality and client satisfaction, make us the ideal partner for ensuring the safety of your products, streamlining regulatory submissions, and building a reputation for quality and reliability.

Contact us today to discuss your specific nonclinical toxicology needs and embark on a journey towards safer products, healthier lives, and a brighter future.

Southern Research News

Radyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences Commercialization

March 13, 2024

Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Southern Research, a Birmingham-based contract research organization with more than 80 years of experience in drug discovery and development. This partners...
Read More

Southern Research opens new Station 41 biotech incubator for startups

January 23, 2024

Today, Southern Research marked the official opening of its Station 41 biotech incubator, which is one of four programs that make up the newly launched Station 41 biotech commercialization hub. The incubator provides wet lab space and office space, shared lab equipment and services to support ...
Read More

Birmingham receives federal Tech Hub designation and opportunity to apply for millions in federal funding

October 23, 2023

Birmingham’s metro area is among 31 regions across the country named today as a federal Tech Hub, competing successfully under a new program that could ultimately inject $75 million into the local economy. The designation followed a highly competitive process with nearly 200 application...
Read More